Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCL2 positive
i
Other names:
BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
596
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCL2 positive
Diffuse Large B Cell Lymphoma
BCL2 positive
Diffuse Large B Cell Lymphoma
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
BCL2 positive
Estrogen Receptor Positive Breast Cancer
BCL2 positive
Estrogen Receptor Positive Breast Cancer
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
BCL2 positive
Diffuse Large B Cell Lymphoma
BCL2 positive
Diffuse Large B Cell Lymphoma
methotrexate
Sensitive: C3 – Early Trials
methotrexate
Sensitive
:
C3
methotrexate
Sensitive: C3 – Early Trials
methotrexate
Sensitive
:
C3
BCL2 positive
Diffuse Large B Cell Lymphoma
BCL2 positive
Diffuse Large B Cell Lymphoma
pixantrone
Sensitive: C3 – Early Trials
pixantrone
Sensitive
:
C3
pixantrone
Sensitive: C3 – Early Trials
pixantrone
Sensitive
:
C3
BCL2 positive
Diffuse Large B Cell Lymphoma
BCL2 positive
Diffuse Large B Cell Lymphoma
venetoclax + polatuzumab vedotin-piiq
Sensitive: C3 – Early Trials
venetoclax + polatuzumab vedotin-piiq
Sensitive
:
C3
venetoclax + polatuzumab vedotin-piiq
Sensitive: C3 – Early Trials
venetoclax + polatuzumab vedotin-piiq
Sensitive
:
C3
BCL2 positive
Diffuse Large B Cell Lymphoma
BCL2 positive
Diffuse Large B Cell Lymphoma
venetoclax + ibrutinib
Sensitive: D – Preclinical
venetoclax + ibrutinib
Sensitive
:
D
venetoclax + ibrutinib
Sensitive: D – Preclinical
venetoclax + ibrutinib
Sensitive
:
D
BCL2 positive
Diffuse Large B Cell Lymphoma
BCL2 positive
Diffuse Large B Cell Lymphoma
venetoclax + fostamatinib
Sensitive: D – Preclinical
venetoclax + fostamatinib
Sensitive
:
D
venetoclax + fostamatinib
Sensitive: D – Preclinical
venetoclax + fostamatinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login